HIV Reservoirs

Jurkat-derived (J-Lat, J1.1 and Jurkat E4) and CEM-derived T cell lines (8E5, ACH-2) as Models of Reversible Proviral Latency.- U1 and OM10.1. Myeloid Cell Lines as Surrogate Models Of Reversible Proviral Latency.-&nbsp;An In Vitro System to Model the Establishment and Reactivation of HIV-1 Latencyin primary human CD4+ T cells.-&nbsp;The cultured T_CM model of HIV latency.-&nbsp;A Reliable Primary Cell Model for HIV latency: The QUECEL (Quiescent Effector Cell Latency) Method.-&nbsp;TGF-b signaling supports HIV latency in a Memory CD4+ T cell based in vitro model.p&nbsp;Flow Cytometry Sorting of Memory CCR6⁺CD4⁺ T-Cells for HIV Reservoirs Quantification.-&nbsp;Human monocyte-derived macrophages (MDM) - Model 1 (GM-CSF).- Human monocyte-derived macrophages (MDM) - Model 2.- Modeling HIV latency in astrocytes with the human neural progenitor cell line HNSC.100.-&nbsp;Hematopoietic stem and progenitor cells (HSPCs).-&nbsp;HIV reservoirs: Modeling, Quantification and Approaches to a Cure.-&nbsp;More than a gender issue: Testis as a distinctive HIV reservoir and its implication for viral eradication.-&nbsp;Experimental Models to Study HIV Latency Reversal from Male Genital Myeloid Cells.-&nbsp;Decidua basalis: An ex vivo Model to Study HIV-1 Infection during Pregnancy and Beyond.-&nbsp;HIV Reservoirs: Modeling, Quantification, and Approaches to a Cure.-&nbsp;Human Hematopoietic Stem Cell (HSC)-Engrafted NSG Mice for HIV Latency Research.-&nbsp;Inducing long-term HIV-1 latency in the TKO-BLT mouse model.-&nbsp;In situ multiplexing to identify, quantify, and phenotype the HIV-1/SIV reservoir within lymphoid tissue.-&nbsp;Single-cell multiparametric analysis of rare HIV-infected cells identified by duplexed RNAflow-FISH.-&nbsp;Ex vivo differentiation of resting CD4+ T lymphocytes enhances detection of replication competent HIV-1 in viral outgrowth assays.-&nbsp;Quantitative Viral Outgrowth Assay to Measure the functional SIV Reservoir in Myeloid Cells.-&nbsp;Near-full-length single-genome HIV-1 DNA sequencing.- TILDA: Tat/rev Induced Limiting Dilution Assay.- Latency Reversal and Clearance of Persistent HIV Infection.- Cure and long-term remission strategies.- Pathways Toward a Functional HIV-1 Cure: Balancing Promise and Perils for CRISPR Therapy.<p>&nbsp;<br></p>

<p>&nbsp;</p>

<p>&nbsp;</p>

<p>&nbsp;</p>